These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 27329400)

  • 1. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial.
    Vitulo P; Stanziola A; Confalonieri M; Libertucci D; Oggionni T; Rottoli P; Paciocco G; Tuzzolino F; Martino L; Beretta M; Callari A; Amaducci A; Badagliacca R; Poscia R; Meloni F; Refini RM; Geri P; Baldi S; Ghio S; D'Alto M; Argiento P; Sofia M; Guardamagna M; Pezzuto B; Vizza CD
    J Heart Lung Transplant; 2017 Feb; 36(2):166-174. PubMed ID: 27329400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension.
    Blanco I; Gimeno E; Munoz PA; Pizarro S; Gistau C; Rodriguez-Roisin R; Roca J; Barberà JA
    Am J Respir Crit Care Med; 2010 Feb; 181(3):270-8. PubMed ID: 19875684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
    Simonneau G; Rubin LJ; Galiè N; Barst RJ; Fleming TR; Frost AE; Engel PJ; Kramer MR; Burgess G; Collings L; Cossons N; Sitbon O; Badesch DB;
    Ann Intern Med; 2008 Oct; 149(8):521-30. PubMed ID: 18936500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe pulmonary hypertension associated with COPD: hemodynamic improvement with specific therapy.
    Girard A; Jouneau S; Chabanne C; Khouatra C; Lannes M; Traclet J; Turquier S; Delaval P; Cordier JF; Cottin V
    Respiration; 2015; 90(3):220-8. PubMed ID: 26277885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study.
    Dumas de La Roque E; Savineau JP; Metivier AC; Billes MA; Kraemer JP; Doutreleau S; Jougon J; Marthan R; Moore N; Fayon M; Baulieu EÉ; Dromer C
    Ann Endocrinol (Paris); 2012 Feb; 73(1):20-5. PubMed ID: 22280813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension.
    Vizza CD; Sastry BK; Safdar Z; Harnisch L; Gao X; Zhang M; Lamba M; Jing ZC
    BMC Pulm Med; 2017 Feb; 17(1):44. PubMed ID: 28228114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.
    Lederer DJ; Bartels MN; Schluger NW; Brogan F; Jellen P; Thomashow BM; Kawut SM
    COPD; 2012 Jun; 9(3):268-75. PubMed ID: 22360383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.
    Lewis GD; Shah R; Shahzad K; Camuso JM; Pappagianopoulos PP; Hung J; Tawakol A; Gerszten RE; Systrom DM; Bloch KD; Semigran MJ
    Circulation; 2007 Oct; 116(14):1555-62. PubMed ID: 17785618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Sildenafil Citrate on Pulmonary Arterial Systolic Pressure and Sub-maximal Exercise Capacity in Chronic Obstructive Pulmonary Disease.
    Shrestha SK; Srivastava B; Karki M; Khatri DB; Pradhan RM
    Kathmandu Univ Med J (KUMJ); 2017 Oct.-Dec.; 15(60):271-278. PubMed ID: 30580340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study.
    Sastry BK; Narasimhan C; Reddy NK; Raju BS
    J Am Coll Cardiol; 2004 Apr; 43(7):1149-53. PubMed ID: 15063421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial.
    Blanco I; Santos S; Gea J; Güell R; Torres F; Gimeno-Santos E; Rodriguez DA; Vilaró J; Gómez B; Roca J; Barberà JA
    Eur Respir J; 2013 Oct; 42(4):982-92. PubMed ID: 23429918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial.
    Behling A; Rohde LE; Colombo FC; Goldraich LA; Stein R; Clausell N
    J Card Fail; 2008 Apr; 14(3):189-97. PubMed ID: 18381181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
    Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
    Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension.
    Barst RJ; Ivy DD; Gaitan G; Szatmari A; Rudzinski A; Garcia AE; Sastry BK; Pulido T; Layton GR; Serdarevic-Pehar M; Wessel DL
    Circulation; 2012 Jan; 125(2):324-34. PubMed ID: 22128226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial.
    Ghofrani HA; Wiedemann R; Rose F; Schermuly RT; Olschewski H; Weissmann N; Gunther A; Walmrath D; Seeger W; Grimminger F
    Lancet; 2002 Sep; 360(9337):895-900. PubMed ID: 12354470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ambrisentan therapy for pulmonary arterial hypertension.
    Galié N; Badesch D; Oudiz R; Simonneau G; McGoon MD; Keogh AM; Frost AE; Zwicke D; Naeije R; Shapiro S; Olschewski H; Rubin LJ
    J Am Coll Cardiol; 2005 Aug; 46(3):529-35. PubMed ID: 16053970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of oral sildenafil in children with Down syndrome and pulmonary hypertension.
    Beghetti M; Rudzinski A; Zhang M
    BMC Cardiovasc Disord; 2017 Jul; 17(1):177. PubMed ID: 28676038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
    Voswinckel R; Reichenberger F; Enke B; Kreckel A; Krick S; Gall H; Schermuly RT; Grimminger F; Rubin LJ; Olschewski H; Seeger W; Ghofrani HA
    Pulm Pharmacol Ther; 2008 Oct; 21(5):824-32. PubMed ID: 18657627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of Sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: A meta-analysis.
    Hao Y; Zhu Y; Mao Y; Xu J; He X; Huang S; Wang M; Qiu J
    Life Sci; 2020 Sep; 257():118001. PubMed ID: 32634428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STARTS-2: long-term survival with oral sildenafil monotherapy in treatment-naive pediatric pulmonary arterial hypertension.
    Barst RJ; Beghetti M; Pulido T; Layton G; Konourina I; Zhang M; Ivy DD;
    Circulation; 2014 May; 129(19):1914-23. PubMed ID: 24637559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.